AIM ImmunoTech Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

AIM$0.14-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at December 31, 2023 and 2022

December 31, 2023 and 2022

(in thousands, except for share and per share amounts)

	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$5,439	$27,053
Marketable investments	7,631	7,137
Funds receivable from New Jersey net operating loss	1,184	1,676
Prepaid expenses and other current assets	302	455
Total current assets	14,556	36,321
Property and equipment, net	127	195
Right of use asset, net	697	829
Patent and trademark rights, net	2,313	1,941
Other assets	1,688	1,202
Total assets	$19,381	$40,488
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$6,443	$377
Accrued expenses	1,986	806
Current portion of operating lease liability	223	178
Total current liabilities	8,652	1,361
Long-term liability:
Operating lease liability	495	659
Total liabilities	9,147	2,020
Commitments and contingencies (Notes 8, 10, 11, 16)	-	-
Stockholders’ equity:
Series A Junior Participating Preferred Stock, $0.001 par value, 4,000,000 and 250,000 shares authorized as of December 31, 2023 and 2022, respectively; issued and outstanding – none	—	—
Series B Convertible Preferred Stock, stated value $1,000 per share, 10,000 shares authorized; 689 and 696 issued and outstanding as of December 31, 2023 and 2022, respectively	689	696
Common Stock, $0.001 par value, authorized shares - 350,000,000; issued and outstanding shares 49,102,484 and 48,084,287 (including 701,667 and 694,324 of unvested stock awards) as of December 31, 2023 and 2022, respectively	49	48
Additional paid-in capital	419,004	418,270
Accumulated deficit	(409,508)	(380,546)
Total stockholders’ equity	10,234	38,468
Total liabilities and stockholders’ equity	$19,381	$40,488

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Years ended December 31,
	2023	2022
Revenues:
Clinical treatment programs – US	$202	$141
Total Revenues	202	141
Costs and Expenses:
Production costs	42	—
Research and development	10,939	6,990
General and administrative	21,137	13,074
Total Costs and Expenses	32,118	20,064
Operating loss	(31,916)	(19,923)
Gain (loss) on investments	200	(1,679)
Interest and other income	1,069	629
Gain on sale of fixed assets	18	3
Redeemable warrants valuation adjustment	—	35
Gain from sale of income tax operating losses	1,667	1,490
Net Loss	$(28,962)	$(19,445)
Basic and diluted loss per share	$(0.60)	$(0.40)
Weighted average shares outstanding basic and diluted	48,585,404	48,047,288

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands except share data)

For the Year Ended December 31, 2023

	Series B	Common Stock	Common Stock .001	Additional Paid-in	Accumulated other Comprehensive	Accumulated	Total Stockholders’
	Preferred	Shares	Par Value	Capital	Income (Loss)	Deficit	Equity
Balance December 31, 2022	$696	48,084,287	$48	$418,270	$—	$(380,546)	$38,468
Common stock issuance, net of costs	—	1,017,399	1	484	—	—	485
Equity-based compensation	—	—	—	243	—	—	243
Series B preferred shares converted to common shares	(7)	798	—	7	—	—	—
Net comprehensive loss	—	—	—	—	—	(28,962)	(28,962)
Balance December 31, 2023	$689	49,102,484	$49	$419,004	$—	$(409,508)	$10,234

For the Year Ended December 31, 2022

	Series B	Common Stock	Common Stock .001	Additional Paid-in	Accumulated other Comprehensive	Accumulated	Total Stockholders’
	Preferred	Shares	Par Value	Capital	Income (Loss)	Deficit	Equity
Balance December 31, 2021	$715	47,994,672	$48	$417,217	$—	$(361,101)	$56,879
Common stock issuance, net of costs	—	88,749	—	80	—	—	80
Equity-based compensation	—	—	—	954	—	—	954
Cashless warrant conversion	—	638	—	—	—	—	—
Series B preferred shares converted to common shares	(19)	228	—	19	—	—	—
Net comprehensive loss	—	—	—	—	—	(19,445)	(19,445)
Balance December 31, 2022	$696	48,084,287	$48	$418,270	$—	$(380,546)	$38,468

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.